STOCK TITAN

Berkeley Lights to Report Third Quarter 2022 Financial Results on November 8, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Berkeley Lights, Inc. (Nasdaq: BLI) will report its financial results for the third quarter of 2022 after market close on November 8, 2022. They will host a conference call at 1:30 p.m. Pacific Time. The call will be accessible via their website and will also be available for replay afterward. Berkeley Lights focuses on digital cell biology, providing a platform for rapid development and commercialization of biotherapeutics, utilizing advanced automation systems and proprietary consumables.

Positive
  • Upcoming Q3 2022 financial results reporting may provide insights into company performance.
  • Strong focus on digital cell biology positions the company in a growing sector.
Negative
  • The timing of the Q3 results reporting indicates a period of uncertainty until the announcement.

EMERYVILLE, Calif., Oct. 18, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay after the event. 

About Berkeley Lights

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. 

Forward-Looking Statements 

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company's growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-to-report-third-quarter-2022-financial-results-on-november-8-2022-301651314.html

SOURCE Berkeley Lights, Inc.

FAQ

When will Berkeley Lights report Q3 2022 financial results?

Berkeley Lights will report its Q3 2022 financial results on November 8, 2022.

What time is the conference call for Berkeley Lights' Q3 2022 results?

The conference call will begin at 1:30 p.m. Pacific Time.

Where can I listen to the Q3 2022 financial results conference call for BLI?

The conference call can be accessed on the Investors section of Berkeley Lights' website.

bli

NASDAQ:BLI

BLI Rankings

BLI Latest News

BLI Stock Data

86.61M
53.95M
15.07%
70.31%
4.11%
Biotechnology
Healthcare
Link
United States
EmeryVille